Surfaces are often considered to play a passive role in clinical mycology; that is, the outward face of a medical device to which fungal cells attach and form biofilms. However, materials chemistry and nanotechnology are now transforming passive surfaces into active interfaces and driving innovation into antifungal agents, their surface delivery and mechanisms, and diagnostic devices. Beyond technological improvements, there is great opportunity to drive basic research into fungal-surface interactions; however, this can only be accomplished with combined and concerted efforts of materials scientists, polymer chemists and mycologists. shown this strategy to be remarkably effective against Candida spp.
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Fungal biofilms on medical devices
Implanted devices are the source of 81% of nosocomial infections 1 , costing the US $5-10 billion per year 2 . Fungal pathogens are the third most common cause of infections from catheters, leading to candidaemia 3 , which has a mortality rate greater than 50% in Moving from 2D to 3D: through the envelope Tethering agents to the surface is a particularly attractive idea because it may be possible to formulate surface coatings using antifungal agents too toxic to be administered systemically. For some of the polyene class of drugs, which associate with ergosterol in the fungal cell membrane, many effective compounds have been developed but cannot be used because of their toxicity profile. One challenge that must be overcome using the tethering strategy is delivery of the agent to the cell membrane, which is protected by the thick cell wall. Using polymer surface grafting techniques it is possible to design nanoscale control of the linker with desired length, density and rigidity or fluidity. Such 3D approaches have successfully been used to study fibroblast adhesion by locating cell binding peptides onto and within so-called polymer brushes 7 .
Beyond the delivery of antifungal agents, this technology could be harnessed to probe structures within the cell envelope to investigate changes in cell wall components that are important in morphogenesis and virulence 8 . This could be studied using live-cell imaging techniques allowing real-time monitoring of morphological changes to the hyphal filaments biochemistry, and cellular biology. Compared to anti-bacterial surfaces, progress has been slow in antifungal surfaces, evidenced by a 10:1 ratio of publications in these fields to date 10 . Clearly there is a disconnect between the importance of this topic to human health and the research outputs, despite calls by key opinion leaders for new strategies and therapies to combat invasive fungal infections 3, 11 and labelling fungi as 'the unknown superbugs' 12 . The Mycology/ Surface Interfaces Group is beginning to address these research gaps through basic research understanding of fungal-surface interactions. Part of this will feed into a greater understanding of clinically relevant poly-microbial infections 13 . Broader research will seek to apply discoveries to other areas including food and water safety, environmental moulds, and new diagnostic devices. Our long term goal is to develop partnerships with industries and translate research outcomes into innovative new products and therapies.
